Conclusions

• Canadian data demonstrates no NTDs among neonates exposed to dolutegravir
• No difference in the rate of congenital anomalies in neonates exposed to dolutegravir during pregnancy
• However, 3-fold higher rate of congenital anomalies in neonates with elvitegravir exposure in the first trimester (10.7%)